Evolent Health Q2 2024 Adj EPS $0.30 Beats $0.26 Estimate, Sales $647.14M Beat $636.44M Estimate
Portfolio Pulse from Benzinga Newsdesk
Evolent Health (NYSE:EVH) reported Q2 2024 adjusted EPS of $0.30, beating the analyst estimate of $0.26 by 15.38%. The company also reported sales of $647.14 million, surpassing the estimate of $636.44 million by 1.68%. This represents a 37.94% increase over the same period last year.
August 08, 2024 | 8:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evolent Health reported strong Q2 2024 earnings, with EPS and sales both beating analyst estimates. The company's sales also showed a significant year-over-year increase of 37.94%.
The strong earnings report, with both EPS and sales beating estimates, and a significant year-over-year sales increase, is likely to positively impact EVH's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100